Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M
Synergy Pharmaceuticals $SGYP is following up on the late-stage success of its lead drug plecanatide for chronic idiopathic constipation with a new batch of upbeat Phase III data centered on irritable bowel syndrome with constipation. The study was conducted among 1,135 patients and the biotech says it will now follow up with a new application in Q1 2017. Synergy is already looking at a PDUFA date of January 29 for its first indication. The company’s shares spiked 6% on the news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.